FLUOCINOLONE ACETONIDE
Clinical safety rating: safe
Animal studies have demonstrated safety
Fluocinolone acetonide is a potent corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress inflammatory cytokines (e.g., IL-1, IL-2, TNF-α). It also causes vasoconstriction and decreases cellular migration and immune response.
| Metabolism | Primarily hepatic via cytochrome P450 enzymes (CYP3A4) to inactive metabolites; also undergoes local metabolism in skin. |
| Excretion | Primarily hepatic metabolism with renal excretion of metabolites (approximately 80% renal, 20% biliary/fecal). Less than 1% excreted unchanged in urine. |
| Half-life | Terminal elimination half-life is approximately 1.3-1.5 hours following topical application; after systemic absorption (oral or injection), half-life is 1.5-2.0 hours, necessitating multiple daily dosing for sustained effect. |
| Protein binding | Approximately 90% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin. |
| Volume of Distribution | 0.2-0.3 L/kg in adults; distributes extensively into tissues with higher concentrations in skin and synovial spaces after local administration. |
| Bioavailability | Topical: very low systemic absorption (approximately 1-2% through intact skin, up to 10-20% through damaged skin or with occlusion); oral: 20-40% due to first-pass metabolism; intra-articular: nearly 100% locally with minimal systemic exposure. |
| Onset of Action | Topical: within 2-4 hours for anti-inflammatory effect; intralesional: 1-2 days; intra-articular: 24-48 hours. |
| Duration of Action | Topical: 6-12 hours after single application; intralesional: 1-3 weeks; intra-articular: 3-4 weeks. Duration prolonged with occlusive dressings or depot formulations. |
Topical: Apply thin film to affected area 2-4 times daily. Otic: 0.01% solution, 5 drops into ear canal twice daily. Intralesional: 3.3 mg/mL, 0.5-1 mL per injection every 1-2 weeks.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for renal impairment as systemic absorption is minimal with topical use. |
| Liver impairment | No dose adjustment required for hepatic impairment due to minimal systemic absorption. |
| Pediatric use | Topical: Apply sparingly to affected area 2-3 times daily. Limit treatment duration to avoid systemic effects. Use lowest potency formulation; not recommended for prolonged use in children under 2 years. |
| Geriatric use | Use with caution due to increased skin fragility and potential for systemic absorption. Apply sparingly and limit duration. Monitor for cutaneous adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Systemic absorption can occur with extensive use.
| Breastfeeding | Excretion in breast milk is unlikely after topical application, but systemic absorption could occur with extensive use. The M/P ratio is unknown. Caution is advised: avoid application to the breast area before nursing, and use the lowest effective dose for the shortest duration. |
| Teratogenic Risk | Topical corticosteroids are generally considered low risk in pregnancy. First trimester: No evidence of increased congenital malformations in human studies. Second and third trimesters: Risk of fetal growth restriction and low birth weight with prolonged or high-dose use. Systemic absorption may occur with extensive application, occlusive dressings, or prolonged use. Risk of adrenal suppression in neonate if used near term in high doses. |
■ FDA Black Box Warning
No FDA boxed warnings specific to fluocinolone acetonide; however, systemic absorption of topical corticosteroids may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria.
| Common Effects | Skin atrophy |
| Serious Effects |
["Hypersensitivity to fluocinolone acetonide or any component of the formulation","Untreated bacterial, fungal, viral (e.g., herpes simplex, vaccinia, varicella) or parasitic skin infections","Perioral dermatitis","Rosacea"]
| Precautions | ["HPA axis suppression with prolonged use or application to large areas, occlusive dressings, or damaged skin.","Cushing's syndrome and hyperglycemia may occur with systemic absorption.","Pediatric patients may be more susceptible to systemic toxicity due to higher skin surface-to-body-weight ratio.","Local adverse reactions including burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration, secondary infection, skin atrophy, striae, and miliaria.","Ophthalmic adverse effects: increased intraocular pressure, cataracts with periorbital use.","Not for ophthalmic use except as specifically indicated (e.g., otic solution)."] |
Loading safety data…
| Fetal Monitoring | Monitor fetal growth by ultrasound if prolonged use of high-potency corticosteroids or large body surface area treatment occurs. Assess for maternal adrenal suppression with extensive use. In neonates after long-term maternal use near term, monitor for transient adrenal suppression. |
| Fertility Effects | No adverse effects on fertility reported in human studies. Animal studies have not shown impairment of fertility at topical doses. |